Galapagos « Terug naar discussie overzicht

Overname van....Gilead....?

3 Posts

Omlaag ↓

diederique 22 september 2016 21:19

kan zomaar gebeuren...

.....The latest idea? That the Dublin drugmaker may target Gilead, whose $107 billion market cap is quite a ways off
of the heights it reached last year.

www.fiercepharma.com/pharma/allergan-...

diederique 23 september 2016 00:25

Will Gilead Make a Good Fit for Allergan?

Allergen’s surprise interest emerged without any earlier indications of interest in companies focused on NASH or liver diseases. Given the backdrop of recent acquisitions, the market is abuzz with rumors about Gilead being the next potential target for Allergan.

www.investopedia.com/news/will-gilead...

diederique 23 september 2016 21:54

Allergan joins a growing field of companies intent on conquering NASH, which include Gilead Sciences Inc. GILD, -0.10% , Bristol-Myers Squibb Co. BMY, +0.23% , Intercept Pharmaceuticals Inc. ICPT, -2.42% , Galmed Pharmaecuticals Ltd. GLMD, -1.64% , Astra-Zeneca Plc AZN, -0.88% and Novartis AG NVS, -0.53% , among others, according to BioMedTracker.

www.marketwatch.com/story/allergan-is...

3 Posts

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	7 mei 2024 17:35
Koers	27,240
Verschil	+0,300 (+1,11%)
Hoog	27,380
Laag	27,020
Volume	74.992
Volume gemiddeld	85.379
Volume gisteren	43.289

Galapagos nieuws meer

14:54	Beursblik: UBS verlaagt koersdoel Gal...
03 mei	Beursblik: hoge cashburn Galapagos	1
02 mei	Galapagos handhaaft verwachte cashburn
01 mei	Aandeelhouders Galapagos keuren alle ...
12 apr	KBC Securities verlaagt koersdoel Gal...
05 apr	Galapagos toont innovatieve aanpak in...
23 feb	AEX op de waakvlam het weekend in, ko...	2
23 feb	Beursblik: gebrek aan opwaarts potent...
23 feb	Gaat AEX op recordjacht of gaat de be...
23 feb	Update : Galapagos voldoet aan verwac...